Patents by Inventor Daniel P. DEVER
Daniel P. DEVER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124895Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: ApplicationFiled: December 5, 2022Publication date: April 18, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Publication number: 20230250423Abstract: The invention provides methods for generating a genetically modified human neural stem cell, genetically modified human neural stem cells, and pharmaceutical compositions comprising the genetically modified human neural stem cells. Also provided are associated kits. The invention also provides methods for preventing or treating a neurodegenerative disease or a neurological injury in a human subject using genetically modified human neural stem cells.Type: ApplicationFiled: January 3, 2023Publication date: August 10, 2023Inventors: Matthew H. PORTEUS, Eric J. KILDEBECK, Daniel P. DEVER, Joseph T. CLARK, Ann TSUKAMOTO, Nobuko UCHIDA
-
Patent number: 11634732Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: GrantFiled: October 15, 2021Date of Patent: April 25, 2023Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Publication number: 20220356450Abstract: The present disclosure provides methods and compositions for genetically modifying hematopoietic stem and progenitor cells (HSPCs), in particular by replacing the HBA1 or HBA2 locus in the HSPCs with a transgene encoding a therapeutic protein.Type: ApplicationFiled: May 9, 2022Publication date: November 10, 2022Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: MATTHEW H PORTEUS, MICHAEL KYLE CROMER, DANIEL P. DEVER, JOAB CAMARENA
-
Patent number: 11492646Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: GrantFiled: October 15, 2021Date of Patent: November 8, 2022Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Publication number: 20220064676Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: ApplicationFiled: October 15, 2021Publication date: March 3, 2022Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Publication number: 20220025409Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: ApplicationFiled: October 15, 2021Publication date: January 27, 2022Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Publication number: 20220025408Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: ApplicationFiled: October 15, 2021Publication date: January 27, 2022Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: DANIEL P. DEVER, RASMUS O. BAK, AYAL HENDEL, WARACHAREE SRIFA, MATTHEW H. PORTEUS
-
Patent number: 11193141Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: GrantFiled: March 21, 2018Date of Patent: December 7, 2021Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Publication number: 20190032091Abstract: In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.Type: ApplicationFiled: March 21, 2018Publication date: January 31, 2019Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daniel P. Dever, Rasmus O. Bak, Ayal Hendel, Waracharee Srifa, Matthew H. Porteus
-
Publication number: 20170298348Abstract: The invention provides methods for generating a genetically modified human neural stem cell, genetically modified human neural stem cells, and pharmaceutical compositions comprising the genetically modified human neural stem cells. Also provided are associated kits. The invention also provides methods for preventing or treating a neurodegenerative disease or a neurological injury in a human subject using genetically modified human neural stem cells.Type: ApplicationFiled: April 13, 2017Publication date: October 19, 2017Inventors: Matthew H. PORTEUS, Eric J. KILDEBECK, Daniel P. DEVER, Joseph T. CLARK, Ann TSUKAMOTO, Nobuko UCHIDA
-
Patent number: 8688467Abstract: Systems and methods for operably coupling medical device(s) together with an evaluation device such that closed-loop processing may occur are provided. To achieve closed-loop processing, the evaluation device is configured to receive diagnostic information related to physiological attributes of a patient and operational-status information of the medical device(s). Upon receipt of this information, the evaluation device may automatically analyze the data and automatically compose instructions based on the analysis. Analyzing includes comparing the data against content within an electronic medical record (EMR) or applying rules to the data. The rules are built on evidence-based medical procedures consistent with current medical practice.Type: GrantFiled: January 9, 2009Date of Patent: April 1, 2014Assignee: Cerner Innovation, Inc.Inventors: Kyle R. Harrison, Lori N. Cross, Daniel P. Devers, Carlos Hernandez, Travis Miner, Arthur J. Hauck, Timothy Jimenez
-
Patent number: 8190447Abstract: Methods for use in, e.g., in-patient care computing environment, for user-centric (e.g., in-patient-centric) selection of at least one menu item are provided. A method in accordance with one embodiment of the present invention may include receiving a plurality of menu item identifiers, each menu item identifier being associated with a different menu item, associating the menu item identifiers with an electronic record associated with an in-patient, displaying the menu item identifiers on at least one patient-viewable display device, and receiving a user selection of at least one of the menu item identifiers. If desired, the method may additionally include filtering the menu item identifiers based on at least one criterion derived from the electronic record to create a set of filtered menu item identifiers and displaying the set of filtered menu item identifiers on the patient-viewable display device rather than the plurality of menu item identifier.Type: GrantFiled: December 16, 2005Date of Patent: May 29, 2012Assignee: Cerner Innovation, Inc.Inventors: Jill R. Hungerford, Charles Cameron Brackett, Daniel P. Devers
-
Publication number: 20100179820Abstract: Systems and methods for operably coupling medical device(s) together with an evaluation device such that closed-loop processing may occur are provided. To achieve closed-loop processing, the evaluation device is configured to receive diagnostic information related to physiological attributes of a patient and operational-status information of the medical device(s). Upon receipt of this information, the evaluation device may automatically analyze the data and automatically compose instructions based on the analysis. Analyzing includes comparing the data against content within an electronic medical record (EMR) or applying rules to the data. The rules are built on evidence-based medical procedures consistent with current medical practice.Type: ApplicationFiled: January 9, 2009Publication date: July 15, 2010Applicant: CERNER INNOVATION INC.Inventors: KYLE R. HARRISON, LORI N. CROSS, DANIEL P. DEVERS, CARLOS HERNANDEZ, TRAVIS MINER, ARTHUR J. HAUCK, TIMOTHY JIMENEZ